- Home
- MAX vs PLRX Comparison
MAX vs PLRX Comparison
Compare MAX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- PLRX
- Stock Information
- Founded
- MAX 2014
- PLRX 2015
- Country
- MAX United States
- PLRX United States
- Employees
- MAX N/A
- PLRX N/A
- Industry
- MAX Industrial Machinery/Components
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MAX Industrials
- PLRX Health Care
- Exchange
- MAX Nasdaq
- PLRX Nasdaq
- Market Cap
- MAX 604.9M
- PLRX 680.3M
- IPO Year
- MAX 2020
- PLRX 2020
- Fundamental
- Price
- MAX $11.87
- PLRX $11.77
- Analyst Decision
- MAX Buy
- PLRX Strong Buy
- Analyst Count
- MAX 8
- PLRX 7
- Target Price
- MAX $22.00
- PLRX $40.50
- AVG Volume (30 Days)
- MAX 375.8K
- PLRX 485.5K
- Earning Date
- MAX 02-24-2025
- PLRX 02-26-2025
- Dividend Yield
- MAX N/A
- PLRX N/A
- EPS Growth
- MAX N/A
- PLRX N/A
- EPS
- MAX 0.19
- PLRX N/A
- Revenue
- MAX $681,230,000.00
- PLRX N/A
- Revenue This Year
- MAX $122.48
- PLRX N/A
- Revenue Next Year
- MAX $32.24
- PLRX N/A
- P/E Ratio
- MAX $62.34
- PLRX N/A
- Revenue Growth
- MAX 72.47
- PLRX N/A
- 52 Week Low
- MAX $10.21
- PLRX $10.22
- 52 Week High
- MAX $25.78
- PLRX $18.00
- Technical
- Relative Strength Index (RSI)
- MAX 54.97
- PLRX 47.63
- Support Level
- MAX $11.02
- PLRX $10.35
- Resistance Level
- MAX $11.78
- PLRX $11.07
- Average True Range (ATR)
- MAX 0.42
- PLRX 0.55
- MACD
- MAX 0.10
- PLRX 0.11
- Stochastic Oscillator
- MAX 73.03
- PLRX 55.75
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.